GlassScriptPhysician profile
Matthew W Schultz
NPI 1043804966
$1,772.79
in general payments reported to CMS, 2019-2025
19 companies · $528 in 2025
The $528 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $84.86 · 2022: $183 · 2023: $302 · 2024: $676 · 2025: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,428 · Education: $76.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,428.10 |
| Education | $76.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $447.69 | 2021-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $209.93 | 2022-2025 | Tremfya, Stelara |
| Ironwood Pharmaceuticals, INC | $162.66 | 2023-2024 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $161.25 | 2022-2025 | Xifaxan, Plenvu |
| Aimmune Therapeutics, INC. | $151.96 | 2024-2025 | Zenpep, Vowst |
| Gilead Sciences, INC. | $108.49 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $90.57 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $66.48 | 2024-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $58.85 | 2021-2022 | |
| Abbvie INC. | $53.18 | 2023-2025 | |
| Celgene Corporation | $47.67 | 2022-2023 | Zeposia |
| Pfizer INC. | $46.04 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $39.07 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $36.90 | 2025 | Iqirvo |
| Lilly USA, LLC | $30.43 | 2025 | Omvoh |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $18.95 | 2023 | |
| Madrigal Pharmaceuticals | $15.71 | 2024 | Resmetirom |
| Braintree Laboratories, INC. | $14.95 | 2024 | Suflave |
| E.R. Squibb & Sons, L.L.C. | $12.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.